Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + MEC in Relapsed/Refractory AML
NCT03118466Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenalidomide in acute myeloid leukemia (AML), sponsored by Massachusetts General Hospital. Primary endpoint: Complete Response Rate at 45 days. Started Sep 2017; status: completed.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03118466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118466.